8.31
Precedente Chiudi:
$8.56
Aprire:
$8.77
Volume 24 ore:
317.06K
Relative Volume:
1.01
Capitalizzazione di mercato:
$396.90M
Reddito:
$36.90M
Utile/perdita netta:
$-166.28M
Rapporto P/E:
-2.5258
EPS:
-3.29
Flusso di cassa netto:
$-203.53M
1 W Prestazione:
+2.85%
1M Prestazione:
+11.99%
6M Prestazione:
-38.72%
1 anno Prestazione:
-62.79%
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Nome
Bicycle Therapeutics Plc Adr
Settore
Industria
Telefono
011441223261503
Indirizzo
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Confronta BCYC con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BCYC
Bicycle Therapeutics Plc Adr
|
8.31 | 559.57M | 36.90M | -166.28M | -203.53M | -3.29 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-08 | Iniziato | Stephens | Equal-Weight |
2024-09-06 | Iniziato | RBC Capital Mkts | Outperform |
2024-08-07 | Downgrade | B. Riley Securities | Buy → Neutral |
2023-09-11 | Aggiornamento | B. Riley Securities | Neutral → Buy |
2022-08-31 | Iniziato | Cowen | Outperform |
2022-07-28 | Iniziato | Barclays | Overweight |
2022-07-06 | Ripresa | Canaccord Genuity | Buy |
2022-04-13 | Downgrade | B. Riley Securities | Buy → Neutral |
2022-04-07 | Ripresa | Cantor Fitzgerald | Overweight |
2022-02-14 | Iniziato | Morgan Stanley | Equal-Weight |
2021-12-17 | Iniziato | SVB Leerink | Outperform |
2021-12-09 | Iniziato | Needham | Buy |
2021-09-30 | Iniziato | B. Riley Securities | Buy |
2021-04-20 | Iniziato | JMP Securities | Mkt Outperform |
2020-10-12 | Iniziato | Cantor Fitzgerald | Overweight |
2020-06-12 | Iniziato | Oppenheimer | Outperform |
2020-04-17 | Iniziato | H.C. Wainwright | Buy |
2019-11-14 | Iniziato | ROTH Capital | Buy |
2019-09-11 | Aggiornamento | Goldman | Neutral → Buy |
2019-06-17 | Iniziato | Canaccord Genuity | Buy |
2019-06-17 | Iniziato | Goldman | Neutral |
2019-06-17 | Iniziato | Jefferies | Buy |
2019-06-17 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Bicycle Therapeutics Plc Adr Borsa (BCYC) Ultime notizie
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World
Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World
Principal Financial Group Inc. Purchases 1,695 Shares of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) - Defense World
Teacher Retirement System of Texas Has $465,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Teacher Retirement System of Texas Sells 1,266 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
William Blair Brokers Decrease Earnings Estimates for TLX - Defense World
Principal Financial Group Inc. Boosts Stake in Capri Holdings Limited (NYSE:CPRI) - Defense World
First Northwest Bancorp (FNWB) Expected to Announce Quarterly Earnings on Thursday - Defense World
The Bank of Nova Scotia (TSE:BNS) Receives Average Rating of “Hold” from Analysts - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up – Should You Buy? - Defense World
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com India
Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 7.40 - DWinneX
Bicycle Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com South Africa
How should investors view Bicycle Therapeutics Plc ADR (BCYC)? - uspostnews.com
PBF Energy Inc [PBF] Records 50-Day SMA of $19.79 - knoxdaily.com
UGI Corp [UGI] Records 200-Day SMA of $27.63 - knoxdaily.com
Cellebrite DI Ltd [NASDAQ: CLBT] Sees Increase in Stock Value - knoxdaily.com
Bicycle Therapeutics Plc ADR [BCYC] Shares Fall -0.69 % on Wednesday - knoxdaily.com
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading - MSN
Bicycle Therapeutics Plc ADR Inc. (BCYC) Price Performance: The Role of Supply and Demand - investchronicle.com
Fastenal Co (FAST) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 By Investing.com - Investing.com South Africa
Bicycle therapeutics COO Alistair Milnes sells $16,850 in stock By Investing.com - Investing.com South Africa
Bicycle Therapeutics chief product officer sells shares worth $5,735 - Investing.com
Bicycle Therapeutics CEO Lee Kevin sells shares worth $43,612 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock - Investing.com
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 By Investing.com - Investing.com UK
Bicycle Therapeutics stock hits 52-week low at $8.6 amid downturn By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India
Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa
Bicycle Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com India
Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Jefferies cuts Bicycle Therapeutics price target to $42 from $53 By Investing.com - Investing.com South Africa
Bicycle Therapeutics stock holds $33 target, Buy rating at Rodman By Investing.com - Investing.com South Africa
Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com India
Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India
Bicycle Therapeutics reports promising cancer drug trial results - Investing.com
Bicycle therapeutics CDO Santiago Arroyo sells shares worth $69,646 - Investing.com India
Bicycle Therapeutics exec sells $30k in shares - Investing.com
Bicycle Therapeutics spotlights cancer treatment targets - Investing.com
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Oppenheimer backs Bicycle Therapeutics' BRC platform, reiterates $48 stock PT - Investing.com UK
Bicycle therapeutics CEO sells shares worth over $71k - Investing.com
Europe Peptide Drug Conjugates Market Size & Outlook, 2030 - Grand View Research
South Korea Peptide Drug Conjugates Market Size & Outlook, 2030 - Grand View Research
Bicycle Therapeutics Plc Adr Azioni (BCYC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):